Company intelligence / Profile preview

Celavet

Oxnard, California, United Statescience.com ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Celavet’s OK100 stem cells have been used to treat over 400 horses with tendon and ligament injuries across more than 35 U.S. veterinary centers. Trials demonstrated potential repair of connective tissues without tumor formation or lasting adverse events. The company is planning regulatory submissions based on these results.

Therapeutic areas: RheumatologyOther
Modalities: Stem cell therapyCell therapyPluripotent stem cell therapy
Industry: Veterinary

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of latest available information. Actively seeking out-license opportunities.

Beyond the preview

Go deeper on Celavet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celavet.

Explore the full profile